Form 4 Filing for Jasper Therapeutics, Inc.

Judith Anne Shizuru, a director at Jasper Therapeutics, Inc. (JSPR), was granted a stock option to purchase 7,500 shares of common stock on July 31, 2026. This grant was automatic under the company's Non-Employee Director Compensation Policy. The option has an exercise price of $0.63 per share and will fully vest on August 4, 2027, provided Shizuru continues her service with the company. The option expires on July 31, 2036. This transaction is reported on Form 4.